Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Endometrial cancer is the most common gynaecological cancer, and is associated with endometrial hyperplasia, unopposed oestrogen exposure and adjuvant therapy for breast cancer using selective oestrogen-receptor modulators (SERMs), particularly tamoxifen. Oestrogen and SERMs are thought to be involved in endometrial carcinogenesis through their effects on transcriptional regulation. Ultimately, oestrogen and SERMs affect the transduction of cellular signalling pathways that govern cell growth and proliferation, through downstream effectors such as PAX2 (paired box 2).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · cited 1×
“Both ERα and ERβ are members of the nuclear hormone receptor superfamily and have modular structures and discrete domains for their specific functions as ligand-regulated transcription factor”
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,657
Self-citationAmant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67063-8 · Cited by 1,497
Kunkel, T. A., & Erie, D. A. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133243 · Cited by 1,367
Björnström, L., & Sjöberg, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0486 · Cited by 1,362
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Self-citationHall, J. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7179 · Cited by 1,075
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Pax-2 controls multiple steps of urogenital development
Torres, M., Gómez-Pardo, E., Dressler, G. R., & Gruss, P. (1995) · Development · doi:10.1242/dev.121.12.4057 · Cited by 897
Estrogen receptor pathways to AP-1
Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., & Webb, P. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 870
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Cummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Berry, M., Metzger, D., & Chambon, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07469.x · Cited by 767
Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains
Tanenbaum, D. M., Wang, Y., Williams, S. P., & Sigler, P. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5998 · Cited by 738
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Cancer risk associated with germline DNA mismatch repair gene mutations
Dunlop, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.1.105 · Cited by 688
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Smith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Pax2 contributes to inner ear patterning and optic nerve trajectory
Torres, M., Gómez-Pardo, E., & Gruss, P. (1996) · Development · doi:10.1242/dev.122.11.3381 · Cited by 594
Connections and Regulation of the Human Estrogen Receptor
McDonnell, D. P., & Norris, J. D. (2002) · Science · doi:10.1126/science.1071884 · Cited by 579
Estrogen receptor (ER) β, a modulator of ERα in the uterus
Weihua, Z., Saji, S., Mäkinen, S., Cheng, G., Jensen, E. V., Warner, M., & Gustafsson, J.-Å. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.5936 · Cited by 507
PTEN/MMAC1 mutations in endometrial cancers.
Risinger, J. I., Hayes, A. K., Berchuck, A., & Barrett, J. C. (1997) · PubMed · Cited by 506
Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development
Jepsen, K., Hermanson, O., Onami, T. M., Gleiberman, A. S., Lunyak, V., McEvilly, R. J., Kurokawa, R., Kumar, V., Liu, F., Seto, E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00064-7 · Cited by 503
Getting your Pax straight: Pax proteins in development and disease
Chi, N., & Epstein, J. A. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(01)02594-x · Cited by 483
Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L. W., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.693 · Cited by 478
Ogawa, S. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3505 · Cited by 448
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
Paige, L. A., Christensen, D. J., Grøn, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C.-Y., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3999 · Cited by 412
Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor.
Dressler, G. R., & Douglass, E. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1179 · Cited by 407
Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen.
Szego, C. M., & Davis, J. S. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.4.1711 · Cited by 404
Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J.-Å., & Safe, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5379 · Cited by 401
Estrogen Receptor Mutations in Human Disease
Herynk, M. H., & Fuqua, S. A. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0010 · Cited by 400
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
Favor, J., Sandulache, R., Neuhäuser-Klaus, A., Pretsch, W., Chatterjee, B., Senft, E., Wurst, W., Blanquet, V., Grimes, P., Spörle, R., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13870 · Cited by 391
Umayahara, Y., Kawamori, R., Watada, H., Imano, E., Iwama, N., Morishima, T., Yamasaki, Y., Kajimoto, Y., & Kamada, T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34025-5 · Cited by 389
Estrogen Receptor Activation Function 1 Works by Binding p160 Coactivator Proteins
Webb, P. (1998) · Molecular Endocrinology · doi:10.1210/me.12.10.1605 · Cited by 384
Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma
Barr, F. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204599 · Cited by 383
Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels
Ward, H. W. C. (1973) · BMJ · doi:10.1136/bmj.1.5844.13 · Cited by 375
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 366
Structural Insights into the Mode of Action of a Pure Antiestrogen
Pike, A. C. W., Brzozowski, A. M., Walton, J., Hubbard, R. E., Thorsell, A.-G., Li, Y.-L., Gustafsson, J.-Å., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 347
Selective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 315
Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas
Marques, A. R., Espadinha, C., Catarino, A. L., Moniz, S., Pereira, T., Sobrinho, L. G., & Leite, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8756 · Cited by 305
The Molecular Pharmacology of SERMs
McDonnell, D. P. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00177-0 · Cited by 299
Brophy, P. D., Ostrom, L., Lang, K. M., & Dressler, G. R. (2001) · Development · doi:10.1242/dev.128.23.4747 · Cited by 298
Mechanism of estrogen activation of c-myc oncogene expression.
Dubik, D., & Shiu, R. P. C. (1992) · PubMed · Cited by 294
A PANorama of PAX genes in cancer and development
Robson, E. J. D., He, S.-J., & Eccles, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1778 · Cited by 283
Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis
Wu, H., Chen, Y., Liang, J., Shi, B., Wu, G., Zhang, Y., Wang, D., Li, R., Yi, X., Zhang, H., et al. (2005) · Nature · doi:10.1038/nature04225 · Cited by 273
Self-citationAnalysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.
McInerney, E. M., Tsai, M. J., O'Malley, B. W., & Katzenellenbogen, B. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10069 · Cited by 256
DNA mismatch repair and mutation avoidance pathways
Marti, T. M., Kunz, C., & Fleck, O. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10077 · Cited by 254
Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival
Muratovska, A., Zhou, C., He, S., Goodyer, P., & Eccles, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206766 · Cited by 248
Montano, M. M. (1995) · Molecular Endocrinology · doi:10.1210/me.9.7.814 · Cited by 246
The oncogenic potential of Pax genes.
Maulbecker, C. C., & Gruss, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05890.x · Cited by 241
Abnormalities of the APC/β-catenin pathway in endometrial cancer
Moreno-Bueno, G., Hardisson, D., Sánchez, C., Sarrió, D., Cassia, R., García-Rostán, G., Prat, J., Guo, M., Herman, J. G., Matías-Guiu, X., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205924 · Cited by 237
Watanabe, T., Inoue, S., Ogawa, S., Ishii, Y., Hiroi, H., Ikeda, K., Orimo, A., & Muramatsu, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6915 · Cited by 224
Kaplan, J. A. (1996) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1016/s1053-0770(96)80171-6 · Cited by 211
Ligand‐dependent switching of ubiquitin–proteasome pathways for estrogen receptor
Tateishi, Y., Kawabe, Y.-I., Chiba, T., Murata, S., Ichikawa, K., Murayama, A., Tanaka, K., Baba, T., Kato, S., & Yanagisawa, J. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600472 · Cited by 170
Jordan, V. C., Gapstur, S., & Morrow, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1449 · Cited by 169
Kounelis, S., Kapranos, N., Kouri, E., Coppola, D., Papadaki, H., & Jones, M. W. (2000) · Modern Pathology · doi:10.1038/modpathol.3880062 · Cited by 166
Saffari, B., Jones, L. A., El‐Naggar, A. K., Felix, J. F., George, J., & Press, M. F. (1995) · PubMed · Cited by 162
Pax-2 is a DNA-binding protein in embryonic kidney and Wilms tumor
Gr, D. (1992) · Medical Entomology and Zoology · Cited by 162
Endometrial Cancer Incidence Trends in Europe: Underlying Determinants and Prospects for Prevention
Bray, F., dos Santos Silva, I., Moller, H., & Weiderpass, E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0871 · Cited by 158
K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto, T., Inoue, M., Perantoni, A. O., Buzard, G. S., Miki, H., Tanizawa, O., & Rice, J. M. (1991) · PubMed · Cited by 156
LECCE, G., MEDURI, G., ANCELIN, M., BERGERON, C., & PERROT-APPLANAT, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7322 · Cited by 153
Expression of the PAX2 gene in human fetal kidney and Wilms' tumor.
Eccles, M. R., Wallis, L. J., Fidler, A. E., Spurr, N. K., Goodfellow, P. J., & Reeve, A. E. (1992) · PubMed · Cited by 147
Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146
Ollikainen, M., Abdel‐Rahman, W. M., Moisio, A., Lindroos, A., Kariola, R., Järvelä, I. E., Pöyhönen, M., Bützow, R. C., & Peltomäki, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.055 · Cited by 146
Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo
Webb, P., Nguyen, P., & Kushner, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208501200 · Cited by 139
Schlosshauer, P. W., Ellenson, L. H., & Soslow, R. A. (2002) · Modern Pathology · doi:10.1097/01.mp.0000028573.34289.04 · Cited by 137
A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
Goldstein, S. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00502-5 · Cited by 136
Isolation of Estrogen-Responsive Genes with a CpG Island Library
Watanabe, T., Inoue, S., Hiroi, H., Orimo, A., Kawashima, H., & Muramatsu, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.442 · Cited by 136
Recent and Past Use of Conjugated Estrogens in Relation to Adenocarcinoma of the Endometrium
Shapiro, S., Kaufman, D. W., Slone, D., Rosenberg, L. A., Miettinen, O. S., Stolley, P. D., Rosenshein, N. B., Watring, W. G., Leavitt, T. J., & KNAPP, R. C. (1980) · New England Journal of Medicine · doi:10.1056/nejm198008283030903 · Cited by 135
PAX2 mutations in oligomeganephronia
Salomon, R., Tellier, A.-L., Attié‐Bitach, T., Amiel, J., Vekemans, M. J. J., Lyonnet, S., Dureau, P., Niaudet, P., Gübler, M.-C., & Broyer, M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002457.x · Cited by 131
The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case.
Cazzaniga, G., Daniotti, M., Tosi, S., Giudici, G., Aloisi, A., Pogliani, E., Kearney, L., & Biondi, A. (2001) · PubMed · Cited by 129
Pham, T. A., Hwung, Y. P., Santiso‐Mere, D., McDonnell, D. P., & O’Malley, B. W. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.7.1508220 · Cited by 124
Klotz, D. M., Hewitt, S. C., Korach, K. S., & DiAugustine, R. P. (2000) · Endocrinology · doi:10.1210/endo.141.9.7649 · Cited by 124
Understanding the genotoxicity of tamoxifen?
Phillips, D. H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.839 · Cited by 124
Dehbi, M., Ghahremani, M., Lechner, M. S., Dressler, G. R., & Pelletier, J. (1996) · PubMed · Cited by 122
Pax genes and their role in organogenesis.
Mansouri, A., Goudreau, G., & Gruss, P. (1999) · PubMed · Cited by 121
Saji, S., Omoto, Y., Shimizu, C., Warner, M. N., Hayashi, Y. K., Horiguchi, S.-I., Watanabe, T., Hayashi, S., Gustafsson, J.-Å., & Toi, M. (2002) · PubMed · Cited by 121
Zheng, W., Cao, P., Zheng, M., Kramer, E. E., & Godwin, T. A. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0120 · Cited by 119
PAX3 is expressed in human melanomas and contributes to tumor cell survival.
Scholl, F. A., Kamarashev, J. A., Murmann, O. V., Geertsen, R., Dummer, R., & Schäfer, B. W. (2001) · PubMed · Cited by 118
Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen
Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., & Pearl, M. L. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.461 · Cited by 116
Barkhem, T., Nilsson, S. V., & Gustafsson, J. K. (2004) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200404010-00003 · Cited by 115
PAX genes in development and disease: the role of PAX2 in urogenital tract development
Eccles, M. R., He, S., Legge, M., Kumar, R., Fox, J., Zhou, C., French, M. C., & Tsai, R. W. S. (2002) · The International Journal of Developmental Biology · doi:10.1387/ijdb.12141441 · Cited by 108
Antiestrogens: Mechanisms and actions in target cells
Katzenellenbogen, B. S., Montano, M. M., Goff, P. L., Schodin, D. J., Kraus, W. L., Bhardwaj, B., & Fujimoto, N. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00084-d · Cited by 107
Steitz, J., Br�ck, J., Steinbrink, K., Enk, A., Knop, J. X. F. R., & Tüting, T. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<15::aid-ijc3>3.0.co;2-b · Cited by 106
Metzger, D., Losson, R., Bornert, J.-M., Lemoine, Y., & Chambon, P. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.11.2813 · Cited by 105
Activation of Transcription by Estrogen Receptor α and β Is Cell Type- and Promoter-dependent
Jones, P. S., Parrott, E., & White, I. N. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32008 · Cited by 103
Advances in chromatin remodeling and human disease
Cho, K. S., Elizondo, L. I., & Boerkoel, C. F. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.04.015 · Cited by 102
Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen
Shibutani, S., Ravindernath, A., Suzuki, N., et al. (2000) · Carcinogenesis · doi:10.1093/carcin/21.8.1461 · Cited by 94
Parc, Y. R., Halling, K. C., Burgart, L. J., McDonnell, S. K., Schaid, D. J., Thibodeau, S. N., & Halling, A. C. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<60::aid-ijc9>3.0.co;2-3 · Cited by 88
Critchley, H. O. D., Henderson, T. A., Kelly, R. W., Scobie, G. S., Evans, L. R., Groome, N. P., & Saunders, P. T. K. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020502 · Cited by 87
Uterine papillary serous carcinoma evolves via a p53-driven pathway
Moll, U. M., Chalas, E., Auguste, M., Meaney, D., & Chumas, J. C. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90340-8 · Cited by 86
Nuclear β‐catenin is a molecular feature of type I endometrial carcinoma
Scholten, A., Creutzberg, C. L., den Broek, L. J. C. M. V., Noordijk, E. M., & Smit, V. T. H. B. M. (2003) · The Journal of Pathology · doi:10.1002/path.1402 · Cited by 83
Silberstein, G. B., Dressler, G. R., & Horn, K. V. (2002) · Oncogene · doi:10.1038/sj.onc.1205172 · Cited by 78
McConnell, M. J., Cunliffe, H. E., Chua, L. J., Ward, T. A., & Eccles, M. R. (1997) · Oncogene · doi:10.1038/sj.onc.1201114 · Cited by 77
Oestrogen Receptor Function at Classical and Alternative Response Elements
Kushner, P. J., Agard, D., Feng, W., Lopez, G., Schiau, A., Uht, R., Webb, P., & Greene, G. (2000) · Novartis Foundation Symposia · doi:10.1002/0470870818.ch3 · Cited by 76
PAX2 Gene Mutation in a Family with Isolated Renal Hypoplasia
NISHIMOTO, K., Iijima, K., Shirakawa, T., Kitagawa, K., Satomura, K., Nakamura, H., & Yoshikawa, N. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1281769 · Cited by 75
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells
Sakamoto, T., Eguchi, H., Omoto, Y., Ayabe, T., Mori, H., & Hayashi, S. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00086-2 · Cited by 69
Simoncini, T., Varone, G. L., Fornari, L., Mannella, P., Luisi, M., Labrie, F., & Genazzani, A. R. (2002) · Endocrinology · doi:10.1210/endo.143.6.8749 · Cited by 65
PAX: developmental control genes in cell growth and differentiation.
Stuart, E. T., & Gruss, P. (1996) · PubMed · Cited by 60
PAX genes: what's new in developmental biology and cancer?
Stuart, E., & Gruss, P. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.suppl_1.1717 · Cited by 60
Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat
Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., & Labrie, F. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00087-x · Cited by 59
Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo
Beland, F. A., McDaniel, L. P., & Marques, M. M. (1999) · Carcinogenesis · doi:10.1093/carcin/20.3.471 · Cited by 58
Expression of Pax2 and patterning of the chick inner ear
Hutson, M. R., Lewis, J. E., Nguyen-Luu, D., Lindberg, K. H., & Barald, K. F. (1999) · Journal of Neurocytology · doi:10.1023/a:1007057719025 · Cited by 57
Jazaeri, A. A., Nunes, K. J., Dalton, M. S., Xu, M., Shupnik, M. A., & Rice, L. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204809 · Cited by 57
Eccles, M. R., Yun, K., Reeve, A. E., & Fidler, A. E. (1995) · Europe PMC (PubMed Central) · Cited by 57
Lack of evidence from HPLC 32P-post-labelling for tamoxifenDNA adducts in the human endometrium
Carmichael, P. L. (1999) · Carcinogenesis · doi:10.1093/carcin/20.2.339 · Cited by 55
Nuclear receptor modifications and endocrine cell proliferation
Fu, M., Wang, C., Zhang, X., & Pestell, R. G. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00223-1 · Cited by 54
Wang, Z., Kyo, S., Maida, Y., Takakura, M., Tanaka, M., Yatabe, N., Kanaya, T., Nakamura, M., Koike, K., Hisamoto, K., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205463 · Cited by 54
EXPRESSION OF THE DEVELOPMENTAL AND ONCOGENIC PAX2 GENE IN HUMAN PROSTATE CANCER
Khoubehi, B., Kessling, A. M., Adshead, J., SMITH, G. L., Smith, D., & Ogden, C. W. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66304-5 · Cited by 53
Fournier, B., Gutzwiller, S., Dittmar, T., Matthias, G., Steenbergh, P., & Matthias, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105418200 · Cited by 52
The Effect of SERMs on the Endometrium
GOLDSTEIN, S. R. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04027.x · Cited by 51
Saegusa, M., & Okayasu, I. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00975.x · Cited by 51
Dardes, R. C., Schafer, J. M., Pearce, S. T., Osipo, C., Chen, B., & Jordan, V. C. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6659 · Cited by 50
Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
Brady, H. A., Desai, S. J., Gayo, L. M., Khammungkhune, S., McKie, J. A., O'Leary, E. C., Pascasio, L., Sutherland, M. K., Anderson, D. W., Bhagwat, S. S., et al. (2002) · PubMed · Cited by 49
Promoter Hypermethylation as an Epigenetic Component in Type I and Type II Endometrial Cancers
Risinger, J. I., Maxwell, G. L., Berchuck, A., & Barrett, J. C. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05975.x · Cited by 43
Mining the Complexities of the Estrogen Signaling Pathways for Novel Therapeutics
McDonnell, D. P. (2003) · Endocrinology · doi:10.1210/en.2003-0900 · Cited by 42
Mutations and Amplification of Oncogenes in Endometrial Cancer
Niederacher, D., An, H., Cho, Y., Hantschmann, P., Bender, H., & Beckmann, M. W. (1999) · Oncology · doi:10.1159/000011931 · Cited by 40
Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
Shibutani, S., Suzuki, N., Laxmi, Y. R. S., Schild, L. J., Divi, R. L., Grollman, A. P., & Poirier, M. C. (2003) · PubMed · Cited by 37
Tamoxifen induction of angiogenic factor expression in endometrium
Hague, S. J., Manek, S., Oehler, M. K., MacKenzie, I. Z., Bicknell, R., & REES, M. C. P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600157 · Cited by 35
Target specificity of selective estrogen receptor modulators within human endometrial cancer cells
Bramlett, K. S., & Burris, T. P. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00258-9 · Cited by 34
The Secreted Frizzled Related Protein 2 (SFRP2) Gene Is a Target of the Pax2 Transcription Factor
Brophy, P. D., Lang, K. M., & Dressler, G. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305614200 · Cited by 34
Pole, J. C. M., Gold, L. I., Orton, T. C., Huby, R. D. J., & Carmichael, P. L. (2004) · Toxicology · doi:10.1016/j.tox.2004.07.005 · Cited by 33
Skrzypczak, M., Bièche, I., Szymczak, S., Tozlu, S., Lewandowski, S. A., Girault, I., Radwanska, K., Szczylik, C. A., Jakowicki, J. A., Lidereau, R., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20224 · Cited by 32
Schild, L. J., Divi, R. L., Beland, F. A., Churchwell, M. I., Doerge, D. R., da Costa, G. G., Marques, M. M., & Poirier, M. C. (2003) · PubMed · Cited by 30
Expression of Nuclear Transcription Factor PAX2 in Renal Biopsies of Juvenile Nephronophthisis
Murer, L., Caridi, G., Vella, M. D., Montini, G., Carasi, C., Ghiggeri, G. M., & Zacchello, G. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000065017 · Cited by 28
Is Tamoxifen the Rosetta Stone for Breast Cancer?
Jordan, V. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.338 · Cited by 28
Bryant, W., Snowhite, A. E., Rice, L. W., & Shupnik, M. A. (2004) · Endocrinology · doi:10.1210/en.2004-0825 · Cited by 27
Smith, R. E., & Good, B. C. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100347 · Cited by 26
Sporn, M. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1377 · Cited by 25
Horváth, G., Leser, G., Hahlin, M., & Henriksson, M. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.00009.x · Cited by 24
In Vivo Regulation of Syndecan-3 Expression in the Rat Uterus by 17β-Estradiol
Russo, L. A., Calabro, S. P., Filler, T. A., Carey, D. J., & GARDNER, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004106200 · Cited by 24
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Bartsch, H., Phillips, D. H., Nair, J., Hewer, A. J., Meyberg-Solomeyer, G., & Grischke, E. ‐. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.845 · Cited by 24
Robertson, J. A., Bhattacharyya, S., & Ing, N. H. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00121-6 · Cited by 19
Rácz, A., Brass, N., Hofer, M., Sybrecht, G. W., REMBERGER, K., & Meese, E. U. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.67 · Cited by 18
Castro‐Rivera, E., & Safe, S. H. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00010-4 · Cited by 17
Farnell, Y. Z., & Ing, N. H. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00076-1 · Cited by 11
Pole, J. C. M., Carmichael, P. L., & Griffin, J. L. (2004) · Biomarkers · doi:10.1080/13547500400022192 · Cited by 4
Pax2 in the development of renal and urinary tract diseases.
Joly, D. A., Salomon, R., Amiel, J., Al, T., Attié‐Bitach, T., & Grünfeld, J. (1999) · PubMed · Cited by 2
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Research works printed but not linked: 2
- Lagarda, H., Catasus, L., Arguelles, R., Matias-Guiu, X. & Prat, J. K-ras mutations in endometrial carcinomas with microsatellite instability. J. Pathol. 193, 193–199 (2001). · doi:10.1002/1096-9896(2000)9999:9999<::aid-path769>3.0.co;2-9
- Lax, S. F., Kendall, B., Tashiro, H., Slebos, R. J. & Hedrick, L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88, 814–824 (2000). · doi:10.1002/(sici)1097-0142(20000215)88:4<814::aid-cncr12>3.0.co;2-u
Cited by
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer
Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., Liang, J., Sun, L., Yang, X., Shi, L., et al. (2009) · Cell · doi:10.1016/j.cell.2009.05.050 · Cited by 692
Self-citationThe different roles of ER subtypes in cancer biology and therapy
Thomas, C., & Gustafsson, J.-Å. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3093 · Cited by 654
The unfolding stories of GPR30, a new membrane-bound estrogen receptor
Maggiolini, M., & Picard, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0242 · Cited by 360
“While this is consistent with the fact that OHT is an ERa agonist in this tissue (Shang & Brown 2002, Shang 2006), ERaindependent mechanisms might also be at play.”
Background
Metadata
- Authors
- Shang, Y.
- Affiliations
- Peking University (CN)
- Corresponding author
- Shang, Yongfeng
- ORCID
- Shang, Yongfeng
- Venue
- Nature Reviews Cancer
- Published
- 2006-05
- Volume
- 6
- Issue
- 5
- Pages
- 360-368
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2052024663
- Cited by
- 246
- References
- 153
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 1 · 2022: 14 · 2021: 14 · 2020: 8 · 2019: 10 · 2018: 9 · 2017: 9 · 2016: 10 · 2015: 11 · 2014: 9 · 2013: 15 · 2012: 18
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- estrogen, selective estrogen receptor modulators, tamoxifen, endometrial carcinogenesis, endometrial hyperplasia, breast cancer adjuvant therapy, transcriptional regulation, PAX2, gene expression
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Estrogens, Female, Humans, Endometrial Neoplasms, Selective Estrogen Receptor Modulators, PAX2 Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.